الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 200 |  |  |
| | | from | 200 | | |
Abstract
Background: Alternative and complementary uses of the natural compound have raised expectations for the treatment of hepatocellular cancer (HCC). Objective: The objective of this study was to determine whether Piceatannol (Pic) combined with cisplatin (Cis) has a synergistic effect on N, N-nitrosodiethylamine (DEN)-induced HCC in rats and explore the underlying mechanism. Method: Tissue antioxidant enzymes, malondialdehyde (MDA), and gene expression of nuclear factor erythroid-2 related factor-2 (Nrf-2) and tumor necrosis factor-alpha (TNF-α) were all measured. Hepatic caspase-3 and NAD (P) H quinone oxidoreductase 1 (NQO1) were also tested, as well as Nuclear Factor Kabba B (NF-κB). Histopathological examinations were performed on liver specimens. Results: Piceatannol and/or cisplatin-induced significant improvement in liver function tests with a significant modulation in the gene expression of Nrf-2 and antioxidant enzymes activities associated with a significant decrease in tissue MDA, TNF-α, NF-κB levels, NQO1 activity, and caspase-3 level compared to the HCC group. These results were significant with the Pic and/or Cis combination when compared to the use of each of these agents alone. Conclusion: It can be concluded that piceatannol combined with cisplatin exerts a synergistic anticancer effect by regulating the Nrf-2 and redox status. Also, the addition of piceatannol to HCC treatment protocol with chemotherapeutic drugs might improve the effect of cisplatin and minimize their side effects.